|
KMID : 0880520210570030211
|
|
Chonnam Medical Journal
2021 Volume.57 No. 3 p.211 ~ p.218
|
|
|
Real-World Efficacy and Safety of Dulaglutide in Korean Patients with Type 2 Diabetes Mellitus: A Retrospective Study in a Tertiary Referral Center
|
|
Yoon Jee-Hee
Hong A-Ram
Choi Won-Suk
Park Ji-Yong
Kim Hee-Kyung
Kang Ho-Cheol
|
|
|
Abstract
|
|
|
|
This study was conducted to evaluate the efficacy and safety of once-weekly dulaglutide therapy as add-on to oral antidiabetic drugs (OADs) and basal insulin in Korean patients with type 2 diabetes mellitus (T2DM) in real-world clinical practice. We retrospectively reviewed the medical records of 112 patients who received dulaglutide in a tertiary referral center. The primary efficacy endpoint was a change in glycated hemoglobin (HbA1c) between baseline and 6 months. The secondary endpoints were the percentage of patients achieving HbA1c <7.0% or ≤6.5% and the change of body weight at 6 months. At baseline, the mean HbA1c was 8.7 % (8.8% in the OAD combination and 8.5% in the basal insulin combination group). The mean adjusted HbA1c at 6 months decreased by ?1.13% in all patients (p<0.001), and by ?1.36 and ?0.74% in the OAD combination and basal insulin combination group, respectively. A significant reduction of ?2.9 kg in body weight was observed in all patients at 6 months (p<0.001). Approximately 34.8% and 23.2% of patients achieved HbA1c <7.0% and ≤6.5%, respectively. Higher baseline HbA1c and no previous insulin therapy were associated with positive responses to dulaglutide on multivariate analysis. Mild gastrointestinal issues (23.2%) were the most frequently observed adverse events. Dulaglutide is an effective and durable treatment option as OAD and basal insulin combination therapy in Korean patients with T2DM.
|
|
|
KEYWORD
|
|
|
Dulaglutide, Diabetes Mellitus, Type 2, Blood Glucose
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
 
|